NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









BOOST Pharma

BOOST Pharma

Private
CopenhagenHealthcare & Life Scienceshttps://boostpharma.com/

Last Round

Convertible Debt

Nov 3, 2025

Total Funding Raised

$6.71M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

BOOST Pharma is a clinical-stage biopharmaceutical company that develops novel mesenchymal stem cell therapies for the treatment of rare pediatric skeletal diseases, specifically osteogenesis imperfecta.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cell therapymesenchymal stem cellMSCosteogenesis imperfectaOIregenerative medicinerare disease treatmentpediatric therapybiotechnologyclinical-stage biotechorphan drugallogeneic therapybone disease treatmentbiopharmaadvanced therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BOOST Pharma Comparables

Compare BOOST Pharma with similar companies based on industry and business-model similarity.

BOOST Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mereo BioPharma Group plc
77%
Ultragenyx Pharmaceutical Inc.
71%
AshiBio
71%

BOOST Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Convertible DebtNov 3, 2025
Convertible DebtOct 28, 2025
VC RoundMay 28, 2024
GrantMar 1, 2021
DebtFeb 1, 2021
Pre Seed
Nov 1, 2020

Key People

Founding team and executive leadership

Lilian Walther Jallow

Chief Development Officer (CDO) and co-founder

Founding Team

Hans T. Schambye

Chief Executive Officer

Executive Team

BOOST Pharma Investors

Notable investors and investment history

BOOST Pharma investors
InvestorRounds
Innovation Fund DenmarkGrant
IndustrifondenVC Round, Convertible Debt
The Export and Investment Fund of DenmarkDebt
Karolinska Development ABVC Round, Convertible Debt
BioInnovation InstitutePre Seed
Sound BioventuresConvertible Debt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2026

    Grew 55% QoQ from 11 to 17 employees.

  • Feb 24, 2026

    Grew 71% QoQ from 7 to 12 employees.

BOOST Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BOOST Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BOOST Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersCopenhagen
Employee Range17
Year Founded2020
Last FundingNov 3, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.